Unicycive Therapeutics, Inc. (UNCY) Insider Trading Activity

NASDAQ$6.58
Market Cap
$116.21M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
795 of 827
Rank in Industry
454 of 469

UNCY Insider Trading Activity

UNCY Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
Sells
$0
0

Related Transactions

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Insider Activity of Unicycive Therapeutics, Inc.

Over the last 12 months, insiders at Unicycive Therapeutics, Inc. have bought $0 and sold $0 worth of Unicycive Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Unicycive Therapeutics, Inc. have bought $12,375 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 15,000 shares for transaction amount of $12,375 was made by Schiller Brigitte () on 2022‑05‑16.

List of Insider Buy and Sell Transactions, Unicycive Therapeutics, Inc.

2022-05-16PurchaseSchiller Brigitte
15,000
0.1098%
$0.82
$12,375
-3.07%
Total: 1

UNCY Institutional Investors: Active Positions

Increased Positions23+164.29%1M+23.13%
Decreased Positions4-28.57%47,988-0.93%
New Positions14New342,387New
Sold Out Positions3Sold Out45,074Sold Out
Total Postitions33+135.71%6M+22.2%

UNCY Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vivo Capital, Llc$11,151.008.52%1.79M+652,901+57.42%2025-09-30
Octagon Capital Advisors Lp$6,230.004.76%1M00%2025-09-30
Nantahala Capital Management, Llc$5,851.004.47%939,20200%2025-09-30
Great Point Partners I Lp$4,963.003.79%796,55800%2025-09-30
Vanguard Group Inc$4,105.003.14%658,878+52,925+8.73%2025-09-30
Logos Global Management Lp$2,950.002.26%473,563+<10%2025-09-30
Geode Capital Management, Llc$783.000.6%125,727+66,941+113.87%2025-09-30
Squarepoint Ops Llc$731.000.56%117,327+117,327New2025-09-30
Acuta Capital Partners, Llc$374.000.29%59,985-2,914-4.63%2025-09-30
State Street Corp$342.000.26%54,827+42,304+337.81%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.